NCT03949634 is a Phase 3 clinical trial of PLD in Early Breast Cancer, sponsored by Fudan University.

Who is sponsoring NCT03949634?

NCT03949634 is sponsored by Fudan University.

What drugs are being tested in NCT03949634?

Interventions in NCT03949634: PLD, CTX, Docetaxel, Paclitaxel, Doxorubicin.

What condition does NCT03949634 study?

NCT03949634 studies Early Breast Cancer.

Is NCT03949634 still recruiting?

NCT03949634 is currently status unknown. Last updated 14 May 2019.

Last reviewed 2019-05-14 · How we verify

NCT03949634

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Status unknown Phase 3 Last updated 14 May 2019

What this trial tests

Phase 3 trial testing PLD in Early Breast Cancer in 272 participants. Status unknown.

Timeline

1 September 2017

Primary endpoint
31 October 2019

31 October 2020

Quick facts

Lead sponsor	Fudan University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	272
Start date	1 September 2017
Primary completion	31 October 2019
Estimated completion	31 October 2020
Sites	1 location across China

Drugs / interventions tested

PLD — full drug profile →
CTX
Docetaxel (Docetaxel) — full drug profile →
Paclitaxel — full drug profile →
Doxorubicin (doxorubicin) — full drug profile →

Conditions studied

Early Breast Cancer — all drugs for Early Breast Cancer →

Sponsor

Fudan University

Who can join

Adults 18 to 75, female only, with Early Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, multicenter, open, controlled Post-Marketing Study. 272 early stage female breast cancer patients who were histopathology confirmed with adjuvant chemotherapy indications were enrolled in this study .The subjects will be randomly assigned to one of the two treatment groups at a 1: 1 ratio, and stratified by trastuzumab,age,baseline cardiac risk factors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiac Cachexia: Unaddressed Aspect in Cancer Patients.
Saha S, Singh PK, Roy P, Kakar SS. · · 2022 · cited 20× · PMID 35326441 · DOI 10.3390/cells11060990
Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial.
Tang L, He M, Geng C, Fan Z, et al · · 2025 · PMID 40504550 · DOI 10.1093/oncolo/oyaf101

Verify or expand the search:

Other trials of PLD

Trials testing the same drug.

NCT07109414 — Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) · Phase 2, PHASE3 · active not recruiting
NCT06787612 — Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · Phase 2 · recruiting
NCT06161025 — A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, o · Phase 2, PHASE3 · recruiting
NCT05536102 — The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) · Phase 2 · recruiting
NCT03907969 — A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Ca · Phase 1, PHASE2 · completed

Other recruiting trials for Early Breast Cancer

Currently open trials in the same condition.

NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT06984250 — Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer · recruiting
NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
NCT05827081 — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer · Phase 3 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03949634 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 14 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03949634.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing